Elevation Oncology Inc. (NASDAQ: ELEV)
$3.00
-0.0200 ( -0.66% ) 843.2K
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Market Data
Open
$3.00
Previous close
$3.02
Volume
843.2K
Market cap
$163.64M
Day range
$2.96 - $3.27
52 week range
$0.36 - $5.83
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
3 | Insider transactions | 2 | Mar 04, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
4 | Insider transactions | 1 | Feb 20, 2024 |
8-k | 8K-related | 13 | Jan 23, 2024 |
4 | Insider transactions | 1 | Jan 22, 2024 |
3 | Insider transactions | 2 | Jan 22, 2024 |
8-k | 8K-related | 13 | Jan 22, 2024 |
8-k | 8K-related | 13 | Jan 05, 2024 |